Great Lakes Retirement Inc. Buys 170 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Great Lakes Retirement Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,876 shares of the medical research company’s stock after buying an additional 170 shares during the quarter. Great Lakes Retirement Inc.’s holdings in IQVIA were worth $682,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Jennison Associates LLC lifted its holdings in shares of IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after acquiring an additional 9,578 shares during the last quarter. PGGM Investments lifted its stake in IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares during the last quarter. Fiduciary Alliance LLC purchased a new position in shares of IQVIA during the first quarter valued at approximately $1,864,000. SG Americas Securities LLC grew its stake in shares of IQVIA by 80.1% during the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after buying an additional 20,369 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of IQVIA during the 1st quarter worth approximately $3,365,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on IQV. Barclays cut their price objective on IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Morgan Stanley upped their price target on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. UBS Group upped their target price on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.27.

IQVIA Stock Performance

Shares of IQVIA stock opened at $211.71 on Friday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a market capitalization of $38.59 billion, a PE ratio of 27.49, a P/E/G ratio of 2.22 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a 50-day simple moving average of $238.71 and a two-hundred day simple moving average of $230.92.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.